Concepedia

Jessica M. Grindheim

JM

Statistics

Publications

8

Citations

739

H-Index

8

Active since

2012

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

University of California, Los Angeles

Brigham and Women's Hospital

Jessica M. Grindheim is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and atezolizumab therapy.

ORCID

Publications per year

2012–2022

8

Publications

8

H3K9me3-heterochromatin loss at protein-coding genes enables developmental lineage specification

Dario Nicetto, Greg Donahue, Tanya Jain et al. · Science · 2019 · 245 citations · Full text

, , +17

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Jamie E. Chaft, Filiz Öezkan, Mark G. Kris et al. · Nature Medicine · 2022 · 237 citations · Full text

, , +17

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

Claire F. Friedman, John D. Hainsworth, Razelle Kurzrock et al. · Cancer Discovery · 2021 · 101 citations · Full text

, , +14

Brachypodium distachyon line Bd3-1 resistance is elicited by the barley stripe mosaic virus triple gene block 1 movement protein

Mi Yeon Lee, Lijie Yan, Florien A. Gorter et al. · Journal of General Virology · 2012 · 39 citations · Full text

, , +16

OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study

David P. Carbone, J. Lee, Mark G. Kris et al. · Journal of Thoracic Oncology · 2021 · 39 citations · Full text

, , +12

1–5 of 8